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Abstract	
 
Background 
Current enhanced recovery guidelines suggest that opioid sparing medications should be used for 
analgesia whenever possible following colorectal surgery. The present study aims to assess whether 
postoperative NSAID use is associated with an increased anastomotic leak rate.  
 
Methods 
A systematic review was performed for studies investigating anastomotic leak rate following NSAID use 
versus control after colonic or rectal anastomosis. Meta-analysis was performed to assess for overall risk 
of anastomotic leak with NSAID use, as well as sub-group analysis to compare selective vs non-selective 
NSAIDs and drug-specific NSAID safety profiles. 
 
Results 
Seven studies were included in the final review. Use of an NSAID post-operatively was associated with 
an overall increased risk of anastomotic leakage [OR 1.58 (1.23, 2.03), P = 0.0003]. Non-selective 
NSAIDs were associated with an increased risk [OR 1.79 (1.47, 2.18), P < 0.00001], but selective 
NSAIDs were not. The non-selective NSAID diclofenac was associated with an increased leak rate [OR 
2.79 (1.96, 3.96), P < 0.00001], but ketorolac was not [OR 1.36 (0.89, 2.06), P = 0.16]. 
 
Conclusions 
Great caution must be taken when prescribing NSAIDs following colonic or rectal anastomotic creation. 
The risk and safety profile varies within the NSAID class and further research is needed to clarify which 
NSAIDs are safe for use and which are not. 
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Introduction	
 
It can be argued that no domain within general surgery has undergone as much scrutiny 
and refinement within the last decade as the post-operative management of colorectal patients18. 
With increasing acceptance and implementation of Early Recovery after Surgery (ERAS) 
protocols, much focus has been placed on decreasing the length of hospital stay post-operatively 
without compromising patient safety. Given the myriad of complications associated with opioid 
and narcotic use, a multi-modality approach using non-steroidal anti-inflammatories (NSAIDs) 
for pain control has increasingly become an integral component of patient care in many centers.  
 
 NSAIDs, which act through inhibition of the cyclooxygenase (COX) pathways, have 
been shown to significantly reduce the amount of opioids required post-operatively, while 
simultaneously decreasing pain, shortening duration of ileus and length of hospital stay, and 
improving patient satisfaction47. However, NSAIDS may also have an impact on wound healing, 
which in animal studies has been shown to have an impact on anastomotic leak rates1. 
Anastomotic leaks, a significant and potentially life-threatening complication, lead to 
peritonitis/sepsis, reoperation, and increased mortality. The implications of a clinically 
significant association between NSAIDs and post-operative anastomotic leaks would be far-
reaching, requiring significant reassessment of our current post-operative management regime. 
 
This study aims to determine if NSAID administration given post-operatively following 
colorectal anastomosis increases the incidence of anastomotic leakage. A positive association 
between NSAID use and anastomotic leak rates would indicate that their routine use post-
operatively is not safe and alternatives will need to be found. Furthermore, if a positive 
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association is found we aim to explore this further to determine if this is a class-specific, or even 
drug-specific effect within the broader NSAID class, or if it’s generalizable to all NSAIDs as a 
whole. On the contrary, if it can be proven definitively that there is no association between 
NSAIDs and anastomotic leakage, then more definitive recommendations can be made with 
respect to the use of NSAIDs (such as by the ERAS society), and many institutes/surgeons who 
have been reluctant to implement an opioid sparing approach can confidently and safely alter 
their practice habits. 
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Chapter	1	–	Background	
 
1.1	–	Colorectal	Anastomosis	
 
 A colorectal anastomosis is the restoration of intestinal continuity following the removal 
of a portion of the colon or rectum. Following resection of a portion of the colon, whether for 
malignant or benign causes, two formerly distant portions of the intestine are attached together to 
form an anastomosis. 
 
 Anatomically the intestinal tract can be categorized into two distinct segments, the large 
intestine (colon) and small intestine. The small intestine is the most proximal segment of the two, 
and as the name implies, has the smaller diameter of the two. It functions to absorb the products 
of digestion (carbohydrates, proteins, lipids, and vitamins) into the bloodstream. The large 
intestine, also called the colon, lies distal to the small intestine and its main function is to absorb 
water. Beyond the colon at the very distal end of the gastrointestinal tract lies the rectum and 
anus. The rectum functions act as a temporary storage site for feces. 
 
 Whenever a portion of the colon or rectum is removed, and intestinal continuity is 
restored by reattaching two distant portions of the intestinal tract, a colonic or rectal anastomosis 
is formed. For example, when the proximal half of the colon is resected for a cecal cancer (the 
cecum is the most proximal portion of the large intestine), an anastomosis is made between the 
distal small bowel and the transverse colon (mid-colon). This type of anastomosis is called an 
ileocolic anastomosis. The method by which these two segments of intestine are reattached 
varies based on the surgeon’s preference. Most surgeons will use a stapling device to create the 
anastomosis, however performing a hand-sewn anastomosis, where the two segments of bowel 
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are sutured together, is also accepted. Current research indicates that both techniques give equal 
results with regards to post-operative leak rates13. 
 
1.2	–	Anastomotic	Leakage	 	
 
 The post-operative anastomotic leak is one of the most feared complications following 
any colorectal anastomotic procedure. As the name entails, it arises when there is leakage of 
intestinal contents from the connection where the two segments of bowel are attached. 
Anastomotic leaks are associated not only with significant morbidity (increased length of stay in 
hospital, need for re-operation, need for stoma following reoperation, etc.), but a significantly 
increased mortality rate (from 2.5% up to 15.8%)14. Furthermore, research now suggests that 
following surgery for rectal and colon cancer, anastomotic leakage is associated with an 
increased risk for local cancer recurrence15. 
 
 The overall incidence of anastomotic leakage is generally recorded between 2 to 7%, with 
the lowest incidence found in patients undergoing an ileocolic anastomosis (1 – 3%), and the 
highest incidence found following colo-anal anastomosis (10 – 20%)16. Most leaks become 
clinically apparent (pain, fever, tachycardia, peritonitis, etc.) between post-operative days 5 and 
7, however up to 12% can occur after post-op day 30 with subtle symptoms (low-grade fever, 
prolonged ileus, etc.)17. 
 
 Well documented risk factors for anastomotic leakage include poor pre-operative patient 
health (quantified using the American Society of Anesthesia score – Appendix 1), emergency 
surgery18, prolonged operative time (likely secondary to more difficult dissection and 
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anastomosis)18, obesity19, and anastomotic ischemia (measured using laser Doppler flowmetry)20. 
One area of controversy within the general surgical community is the risk of leakage associated 
with post-operative NSAID usage. This study aims to address this controversial topic and 
provide some clarity into the safety of non-steroidal anti-inflammatory drugs following 
colorectal surgery. 
 
1.3	–	Nonsteroidal	Anti-Inflammatory	Drugs	(NSAIDs)	
 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of medication used 
worldwide for their analgesic (pain-relieving), antipyretic (fever-reducing), and anti-
inflammatory effects. Within the NSAID class there are more than 20 different drugs. The 
primary mechanism of action of these medications is the prevention of prostaglandin synthesis. 
Prostaglandins are a group of hormone-like compounds produced in the body. There are various 
types of prostaglandins producing an array of effects on the human body, but central to their role 
in the inflammatory process is their ability to function as powerful vasodilators. Prostaglandins 
are produced following the oxidation of arachidonic acid by the cyclooxygenase (COX) 
enzymes.     
 
 NSAIDs work by inhibiting one or both of the two important isoforms of the COX 
enzyme: COX-1 and COX-2. COX-1 is expressed in most tissues and is responsible for baseline 
levels of most prostaglandins, while COX-2 is generally undetectable in most tissues and its 
expression is increased during states of inflammation. Reduction in COX enzyme activity leads 
to reduced prostaglandin production, which in-turn leads to impaired tissue inflammatory 
activity. This anti-inflammatory effect has been shown to impair collagen cross-linkage in 
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healing intestinal tissue, which has been shown to decrease the tissue’s mechanical strength25. As 
a result, there has been increasing concern regarding the safety of NSAIDs during colonic and 
rectal anastomotic healing. Similar questions have come up in other surgical fields as well, such 
as within the orthopedic surgery community, where it has been demonstrated that NSAIDs 
impair bone and fracture healing49. 
 
 NSAIDs can be further sub-classified depending on which COX enzyme is affected. 
Non-selective NSAIDs are those that target both the COX-1 and COX-2 enzymes. Due to the 
widespread nature of COX-1, and its multitude of effects, non-selective NSAIDs can lead to a 
variety of side-effects. Chief amongst these is the risk of gastric ulceration secondary to the 
reduction in gastric protection that is normally provided by prostaglandins. As a result, selective 
NSAIDs were created to target just the COX-2 enzyme. These medications produce analgesic 
and anti-inflammatory effects similar to non-selective NSAIDs, but with fewer gastric and 
duodenal ulcers. Despite the dichotomous classification, there are many different drugs within 
the the NSAID class with differing affinities for the COX-1 and COX-2 enzymes. Certain non-
selective NSAIDs, such as diclofenac, have an inhibitory profile that favors the COX-2 enzyme 
to such an extent that they in-effect act very similar to selective NSAIDs39. Furthermore, 
different medications within the NSAID class have differing analgesic properties irrespective of 
their sub-classification. Non-selective NSAIDs such as ibuprofen, ketorolac, and diclofenac have 
been shown to be superior to other non-selective NSAIDs, such as paracetomol, when it comes 
to pain control50. While these drugs are all grouped under one class, they vary significantly in 
their risk and efficacy profiles. 
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1.4	–	Early	Recovery	After	Surgery	(ERAS)	
 
 To understand the importance of NSAID safety following colorectal surgery, one must 
understand the importance and clinical impact the ERAS movement has had on current surgical 
practice. The underlying principle of ERAS (Early Recovery After Surgery) is to provide 
evidence-based protocols to reduce hospital length of stay, and expedite return to baseline health 
and functional status. The ERAS guidelines provide strategies for optimal preoperative, 
intraoperative, and postoperative strategies (See Appendix 2)21.  
 
 Data from hospitals that have implemented the ERAS protocol have shown reduced 
hospital length of stay, earlier return of bowel function, and earlier ambulation22. Taken all 
together, this implies that patients return to their baseline health quicker and returning to work in 
a shorter period of time, hospitals are discharging patients sooner and saving significant amounts 
of money, and most important of all, patients are experiencing significantly fewer healthcare-
associated lung, urinary tract, and surgical site infections23. 
 
 Looking at the current ERAS guidelines for colorectal surgery (Appendix 2), one can see 
the recommendation for opioid-sparing analgesia in the postoperative period. Opioids are known 
to cause sedation, postoperative nausea and vomiting, urinary retention, ileus, and respiratory 
depression24, all of which can delay discharge. The primary pharmacologic alternative to opioids 
are NSAIDs (nonsteroidal anti-inflammatory drugs). However, much debate has lingered in the 
surgical community regarding the safety of NSAIDs following colorectal surgery, and whether 
or not there is an increased risk of anastomotic leakage associated with their usage (See 
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Literature Review). With this systematic review we aim to find an answer to the question – “Are 
NSAIDs associated with an increased risk of anastomotic leakage following colorectal surgery?”. 
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Chapter	2	–	Literature	Review	
 
2.1	-	Animal	Studies		
Introduction	
 
 Any clinical question must be founded on an underlying pathophysiological principle. 
Assessment of tissue and anastomotic healing in human patients can only measure the clinical 
end point of anastomotic leakage. In-vivo assessment of tissue healing on a cellular level cannot 
be done with human patients in the post-operative period. In contrast, assessment of tissue and 
anastomotic healing in animal studies allows for experimental analyses that look at the 
underlying cellular processes that occur during the healing process and how they are affected by 
NSAIDs. When quantifying anastomotic integrity/strength experimentally, two measures that are 
commonly used are anastomotic breaking strength and anastomotic bursting pressure. 
 
Anastomotic breaking (tensile) strength is measured using an instrument called a Lloyd’s 
tensiometer. The two ends of the anastomosis are placed in two separate clamps which are pulled 
apart at a constant speed. The machine produces a load-strain curve which is quantified into a 
score produced by the accompanying software. The anastomotic bursting pressure is measured 
by inserting an oxygen insufflator into the bowel lumen and attaching it to a manometer. The 
intraluminal pressure is increased by gas insufflation in increments of 10 mmHg, and held at 
each pressure for 10 seconds. The bursting pressure is measured as the pressure at which gas 
leakage occurred. Many experimental animal studies use one or both of these measures. 
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Literature	Review	
 
Cahill	RA	et	al.,	200425	
 
 Randomized trial on 40 adult Sprague–Dawley rats who underwent laparotomy, 
descending colonic transection and hand-sewn re-anastomosis. The rats were randomized to 
receive either a selective COX-2 inhibitor (rofecoxib, 10 mg/kg) or an equal volume of water via 
an orogastric tube (tube placed down the throat and into the stomach) before operation and then 
daily after surgery. Animals were euthanized after 3 or 7 days, and their anastomosis was 
assessed using bursting pressure and tensile strength measurement. Haematoxylin and eosin-
stained intestinal sections were also examined and scored by a blinded independent observer. 
 
 Upon final analysis, the researchers found a correlation between NSAID use and 
anastomotic leakage. Five animals in the group receiving rofecoxib developed colonic 
anastomotic complications, compared with none in the control group (P = 0.048). Two had 
developed colonic perianastomotic abscesses by day 3, and three had frank colonic anastomotic 
dehiscence by day 7. When comparing the two groups, the researchers found that the rats that 
had received rofecoxib had markedly lower bursting pressures at both post-op day 3 and 7 (both 
P = 0.02), and similarly the tensile strength was weaker in this group at both time points (P = 
0.04 at day 3). Histologically however, there were no significant differences in the cellular 
(inflammatory cell or fibroblast influx) or structural (blood vessel formation or collagen 
deposition) composition around the anastomoses between the groups. 
 
 The conclusion reached by the team was that COX-2 inhibitors may in-fact significantly 
decrease the wound strength of post-operative colonic anastomosis. The differences in 
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mechanical wound strength, despite the presence of similar degrees of fibroblast influx and 
collagen formation, suggested, according to the authors, that there was an impairment in collagen 
cross-linking in the rats receiving COX-2 inhibitors. 
 
De	Hingh	IH	et	al.,	200626	
 
 Randomized trial whereby male Wistar rats were operated on and received both an ileal 
and a colonic anastomosis, at 15 cm proximal to the cecum and 3 cm proximal to the peritoneal 
reflection. The rats were randomized to receive either celecoxib (a selective COX-2 inhibitor), in 
doses of 15, 50 or 200 mg/kg/day, or normal saline (placebo) daily starting the day before the 
operation. The rats were then euthanized on post-op day 3 and anastomotic strength was assessed 
by measuring the bursting pressure and breaking strength. The team then went on to perform 
histologic and biochemical analysis on the intestinal tissue. 
 
 Administration of celecoxib, at all doses tested, resulted in a significantly higher ileal 
leak rate than in control rats (P = 0.002), but there was no difference in the colonic anastomosis 
leak rates. Ileal bursting pressures were significantly lower in those treated with celecoxib 200 
mg/kg/day than in the control group (P = 0.004), however the colonic bursting pressures were 
not affected by celecoxib. There were no differences in breaking strength in either group for ileal 
nor colonic anastomoses. Finally, and very interestingly, on histologic intestinal analysis of rats 
that had not undergone surgery, COX-2 was undetectable, while in those who had just undergone 
a resection and anastomosis COX-2 was widely expressed in both the ileum and colon.  
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 What the team concluded was that the COX-2 inhibitor impaired the healing of the ileal 
anastomosis, but not the colonic anastomosis. These findings (regarding the effect of COX-2 
inhibitors on colonic anastomoses) are contradictory to those found by Cahill et al. in 2004. The 
team led by de Hingh postulated that this may be secondary to pharmacokinetic difference 
between the different COX-2 inhibitors used in the two studies, however this hypothesis has yet 
to be proven. Never-the-less, the recommendation was made to exercise caution as COX-2 
inhibitors may impair anastomotic healing, in particular with ileal anastomoses.  
 
Klein	M	et	al.,	201127	
 
 Randomized trial on 32 Wistar rats who underwent a descending colon resection with 
primary colonic anastomosis. The rats were randomized to receive either diclofenac (a non-
selective NSAID) at 4mg/kg/24 hours or saline intramuscular injection twice daily. On post-
operative day 3 the rats were euthanized and the breaking strength and COX-2 levels of the 
anastomoses were measured. 
 
 The researchers found a significantly reduced level of COX-2 enzyme in the tissues of 
the rats who received diclofenac, however there were no differences between the two groups in 
anastomotic breaking strength. Furthermore, there was no correlation between COX-2 levels and 
breaking strength. The conclusion of the research team was that while diclofenac decreases the 
COX-2 enzyme levels in the intestinal tissue, this does not pose an increased risk of anastomotic 
leakage, and diclofenac appears to be safe in the early healing of colonic anastomoses. 
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Klein	M	et	al.,	201228	
 
 Randomized trial on 60 Wistar rats who underwent a descending colectomy with colonic 
anastomosis. A separate expanded polytetrafluoroethylene (ePTFE) tube was placed 
subcutaneously into the rats back as well. The tube was to be taken out and analyzed for 
hydroxyproline (an essential component of tissue healing) content on post-op day 7. The rats 
were randomized to receive diclofenac 4mg/kg/day or saline (placebo) post-operatively. The rats 
were then euthanized on post-op day 7 and both the ePTFE tube was removed as well as the 
colonic anastomosis. 
  
 On final analysis, no difference in anastomotic breaking strength was seen between the 
two groups. There was however a 38% decreased collagen deposition level (as estimated by the 
hydroxyproline level) in the ePTFE tubes of the diclofenac group rats (P = 0.03). Collagen is a 
critical component of the tissue healing cascade, however since the anastomotic breaking 
strength was equal in both groups, this decrease was not clinically relevant. Therefore, the 
research team concluded that while diclofenac may cause a histologically significant decrease in 
collage deposition, there is no clinically significant increased risk of anastomotic breakdown 
associated with this. 
 
Van	der	Vijver	RJ	et	al.,	201329	
 
 Two experiments performed on 40 Wistar rats. In the first experiment, 20 rats were given 
a colonic anastomosis 3 cm from the peritoneal reflection (descending colon) as well as a second 
anastomosis in the distal ileum 15cm proximal to the cecum. The rats were then randomized into 
two groups. Group 1 received buprenorphine (an opioid) for post-op analgesia, while group 2 
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received carprofen (a COX-2 inhibitor). For the second experiment, 20 rats were randomized to 
receive either an ileal anastomosis only or a colonic anastomosis only. All the rats in experiment 
2 then went on to receive carprofen for post-op analgesia. 
 
 The rats were euthanized on post-operative day 3 and the anastomoses were examined. In 
experiment one, carprofen was associated with a significantly elevated ileal anastomotic leakage 
rate (P = 0.01), but no change in the colonic leakage rate. In the second experiment, where the 
rats only had 1 anastomosis, the use of carprofen led to an ileal leakage rate of 80%, whereas all 
the colonic anastomoses remained intact (P = .0007).  
 
In assessing the mean bursting pressure, the ileal anastomoses had a significantly lower 
bursting pressure in the carprofen group in experiment 1 than in the control group (P = .0005), 
but there was no significant difference in the breaking strength. The bursting pressure did not 
change for the colonic anastomosis. Finally, the collagen activity level was assessed on all the 
specimens (by measuring the hydroxyproline levels) and no differences were found at the ileal or 
colonic anastomoses across groups. 
 
 The conclusion derived from this study is that the COX-2 inhibitor carprofen impairs 
anastomotic healing in the ileum, but not the colon. These results were similar to those found by 
de Hingh et al, in 200626. The authors cite a 2005 study which describes COX-2 expression as 
being highest in the ileum30, and hypothesize that the elevated expression in the ileum may 
explain why COX-2 inhibition affects ileal anastomoses to a far greater extent than colonic 
anastomoses. The findings from this study suggest caution when using NSAIDs, particularly 
COX-2 inhibitors, following anastomotic creation. 
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Yauw	S	et	al.,	201431		
 
 Study performed on rats aimed at assessing if diclofenac affects anastomoses differently 
depending on the location in the intestine. Ninety-five Wistar rats were randomized to one of 6 
groups. The groups differed based on the location of the anastomosis the rats were given (ileum 
vs proximal colon vs distal colon), and the timing of diclofenac administration (no diclofenac vs 
diclofenac starting post-op day 0 vs post-op day 1 vs post-op day 2). The rats were euthanized 3 
days after starting diclofenac (or post-op day 3 for the group that didn’t receive diclofenac) and 
the leak rate and anastomotic strength was assessed. 
 
 The investigators found that the leak rate did not differ between the ileum and proximal 
colon, however both had significantly higher leak rates than the distal colon (P = 0.001). 
Delaying the administration of diclofenac to post-operative day 1 or 2 resulted in a gradual 
reduction in the leak rates. In assessing the bursting pressure and breaking strength, the only 
significant change that was found was a significantly lower bursting pressure in the ileum 
compared to the distal colon when diclofenac was administered. 
 
 The findings in this study correlate very interestingly with previous rat model findings. 
Diclofenac caused proximal colon leakage rates similar to that observed with ileal anastomoses, 
but had no effect on the distal colon. These results show that in the large bowel, diclofenac only 
affects the healing of the proximal colon anastomosis. Furthermore, the incidence of leakage in 
the proximal colon was significantly lower when administration of diclofenac was delayed one to 
two days. These findings suggest an early detrimental effect from diclofenac on ileal and 
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proximal colon anastomoses, and that caution should be taken when prescribing diclofenac as an 
early postoperative painkiller following gastrointestinal surgery. 
 
Drakopoulou	S	et	al.,	201632	
 
 Study designed to assess the affect of lornoxicam (non-selective NSAID) on proximal 
colonic anastomoses. Twenty-eight Wistar rats were randomly assigned to two groups. All rats 
underwent ascending colonic transection followed by a hand-sewn anastomosis. Group 1 
received intraperitoneal lornoxicam before and daily after surgery. Group 2 received an equal 
intraperitoneal volume of placebo. Half of the rats in each group were euthanized on post-op day 
3 and the remaining on post-op day 7. Macro and microscopic indicators of anastomotic healing 
were then assessed. 
 
 The rats in the lornoxicam group did have higher rates of anastomotic leakage, but this 
did not reach statistical significance. On histologic exam, the colonic anastomosis in the 
lornoxicam group was found to have significantly lower fibroblast infiltration levels by post-
operative day 3, and significantly less granulation tissue by post-operative day 7. Fibroblasts are 
critical in wound healing and lay the structural framework for new tissue growth. Similarly, 
granulation tissue is the newly formed tissue bed upon which connective tissue and blood vessels 
form to regenerate tissue. Both these factors are critical to wound healing, and anastamotic tissue 
repair in particular. In keeping with all this, the rate of histologic necrosis was found to be higher 
in the lornoxicam group, an indicator of microvascular ischemia and delayed tissue healing. 
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 The authors conclude that while lornoxicam was not found to significantly increase 
anastomotic dehiscence in the rat model, histological factors associated with the healing process 
of a newly reconstructed colonic anastomosis were shown to be impaired. Taken all together, this 
indicates that there may in-fact be a true detrimental effect attributable to NSAIDs that would be 
borne out in a larger study. Caution is recommended with the use of NSAIDs following colonic 
anastomosis. 
 
Summary	
 
 While there is conflicting animal data regarding the potential association with NSAID use 
and anastomotic leakage, there appear to be a general trend seen in the literature. There appears 
to be a location dependent effect of NSAIDs on anastomotic healing. Three of the studies found 
an association between NSAID use and ileal anastomotic leakage, but when descending colon 
anastomoses were examined that association was no longer present26, 29, 31. Given the increased 
expression of COX-2 in the small bowel compared to the distal colon30, it’s hypothesized that 
COX-2 inhibition may decrease tissue healing with the ileum being affected to a greater extent 
than the distal colon29. This location dependent effect is not simply a matter of small bowel vs 
large bowel anastomosis however. As explained in the study by van der Vijver et al. in 201329, 
proximal colonic anastomoses and ileal anastamoses seem to be affected to a similar degree by 
NSAIDs, yet distal colonic anastomoses show no detrimental effects29. Furthermore, looking at 
the two studies which found no increased risk of leakage following NSAID administration, both 
examined distal colonic anastomoses exclusively27, 28. Their negative findings fall in line with the 
location dependent findings of other studies, and cannot be generalized to state that there is no 
association between NSAID use and anastomotic leakage elsewhere in the gastrointestinal tract. 
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 The pathophysiological mechanism by which NSAIDs may impair anastomotic healing is 
still up for debate. While studies have shown COX-2 expression to be greatest in the ileum30, and 
it has been shown that COX-2 expression is decreased following NSAID use, this has not been 
found to correlate with a lower anastomotic mechanical strength27. Furthermore, the effect that 
NSAIDs have on collagen deposition and cross-linking remains unclear. In 2005 Cahill et al.25 
performed a study where they found no decrease in collagen deposition in intestinal tissue 
following NSAID use, despite a decrease in their mechanical strength. They hypothesized that 
what occurs is an impairment in cross-linkage rather than a change in the amount of collagen 
present. Similarly, in 2013 van der Vijver et al.29 found no change in collagen present in ileal or 
colonic tissues following NSAID usage, despite an increased ileal leak rate. In contrast, in 2012 
Klein et al. 28 found a statistically significant reduction in collagen present in colonic tissue 
following NSAID administration, but no change in the breaking strength of the tissues. 
 
 What can be taken away is that there does seem to be a true, location dependent effect 
that NSAIDs have on the gastrointestinal tract, and histological factors associated with the 
healing process certainly seem to be affected. NSAIDs appears to decrease fibroblast infiltration, 
decrease granulation tissue formation, decrease re-epithelialization, and increase microscopic 
necrosis32. Taken all together this can certainly lead to impaired wound healing and tissue 
regeneration. Finally, while the results and findings across studies are not always consistent, one 
must remember that a variety of NSAIDs are used in these studies, each with their own unique 
pharmacodynamic profile. Not only is there a distinction between selective and non-selective 
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NSAIDs, but within these classes each drug has a different affinity for the COX enzymes, 
resulting in differing physiologic responses. 
 
 
2.2	–	NSAIDs	Post	Colorectal	Anastomosis	(Previous	Meta-Analyses)		
 
Introduction	
 
 Animal studies suggest that NSAIDs may impair anastomotic healing, but the question 
remains: Does this risk translate to real-life, clinical practice? With the current push towards 
non-opioid analgesia in the post-operative period, concrete clinical evidence is needed to 
convince clinicians that the most effective tool in the non-opioid armamentarium, NSAIDs, are 
not safe for routine use. 
 
 The literature regarding NSAID safety following colorectal surgery was, for the most 
part, quite sparse prior to the turn of the century. As more attention was placed on decreasing 
patient length of stay and limiting narcotic use, NSAID use has increased and many have 
questioned if it is safe to do so. In the last 15 years many attempts have been made to tackle this 
question. Some have found an increased risk of leakage with NSAID use, some have not. As the 
number of studies has increased, researchers have begun to combine these results, making an 
effort to increase the statistical power, improve the size effect estimates, and ultimately resolve 
the uncertainty that remains. That is of course the goal of any systematic review and meta-
analysis. 
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Literature	Review	
 
Rushfeldt	CF	et	al.,	201133	
 
 Systematic review from 2011 involving three observational retrospective cohort studies 
(887 patients). Two of the studies assessed post-operative diclofenac use while the other looked 
at celecoxib. All three studies found a significantly increased risk of anastomotic leakage 
following administration of the the NSAID in question. No mention was made in the article 
regarding other confounding factors for anastomotic leakage, or the distribution of such factors 
amongst the three articles. For example, there was no mention of the type of anastomosis in each 
article, the use of a protective ostomy, average length of surgery, pre-existing patient health, etc. 
There were also no secondary outcomes assessed besides anastomotic leakage rate.   
 
 As the first systematic review looking at this topic the warning flag was raised that there 
may be a real risk associated with NSAID use. But as an isolated review there were several 
limiting factors present. The small number of studies, lack of bias assessment, lack of 
confounder assessment, and lack of a final overall quantitative effect estimate all limit 
interpretation of the authors results. The take-away message from this study is that NSAIDs may 
increase the risk of anastomotic leakage, but more evidence would be needed before a definitive 
conclusion could be made.  
 
Burton	TP	et	al.,	201334	
 
 Systematic review and meta-analysis comprised of six randomized control trials (480 
patients). All six studies were designed and powered to assess the effect of NSAID usage on 
post-operative ileus. As a secondary outcome three of these studies quantified the post-operative 
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anastomotic leak rate amongst the NSAID and non-NSAID groups. The other three articles 
mentioned anastomotic leakage in the context of patient exclusion within their study. The six 
included trials involved NSAID usage of any kind, within 48 hours of an anastomosis of the 
small bowel, colon, or rectum. Risk of bias was assessed using the Jadad score35. The primary 
outcome measured in the meta-analysis was anastomotic dehiscence. Secondary outcomes 
measured included pain scores, morphine equivalent doses, and time to return of flatus and 
stools.  
 
 In four of the six trials the incidence of anastomotic dehiscence was higher in the NSAID 
group than in control group. Synthesized, the overall rate of anastomotic leakage was 5.1% in the 
NSAID group vs 2.4% in the control group. Despite an odds ratio of 2.16, this difference did not 
reach statistical significance (P = 0.1).  
 
Most studies showed a moderate beneficial effect from NSAIDs for all secondary end 
points. There was no difference between groups in movement-evoked pain scores on POD 0 or 
POD 1, but they were significantly lower on POD 2. Pain scores at rest were significantly lower 
in the NSAID group on POD 0, 1, and 2. Opioid usage during the first 48 hours was significantly 
lower in the NSAID group, with an average time to return of bowel function 0.43 days earlier in 
the NSAID group in than in the control group (P < 0.00001). 
 
 This meta-analysis illustrates the dilemma that surrounds the NSAID conundrum. On the 
one hand there seems to be an indication that the risk of leak following NSAID usage is 
increased. But this difference does not reach statistical significance. Whether because of an 
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under-powered meta-analysis that failed to demonstrate a true effect, or a difference between 
groups that came about by pure chance, no definitive answer to the clinical question at hand can 
be had. Looking at the articles included within this meta-analysis, one can see that none of the 
six articles assessed anastomotic leakage as a primary, or even pre-determined secondary, 
outcome. As such these studies were not sufficiently powered to give a significant result with 
regards to NSAIDs and anastomotic leakage. In-fact, of the six included studies, three of them 
only mention anastomotic leakage in the context of excluding patients from their study because 
they leaked. This is because all six of these studies were actually designed and powered to assess 
the affect of NSAIDs on post-operative ileus and resumption of bowel function, not anastomotic 
leakage. In this regard, the studies demonstrated a small but significant beneficial effect from 
NSAIDs with regards to improved post-op pain scores, quicker return to bowel function, and 
decreased reliance on opioids. All of which are important clinical measures. Beneficial effects 
like these make NSAIDs an enticing analgesic option for many surgeons, and the lack of 
definitive proof demonstrating increased harm makes it difficult to abandon them. 
 
Bhangu	A	et	al.,	201436	
 
 Systematic review and meta-analysis involving 8 studies (4,464 patients) aimed to assess 
whether postoperative NSAID use increased the risk of anastomotic leakage. Articles that 
involved either a small bowel or colon anastomosis were included. Assessment of bias was 
performed using the Newcastle Ottawa Scale37.  
 
 Overall use of NSAIDs was significantly associated with anastomotic leak (P < 0.001). 
On sub-group analysis, an adverse effect was seen with non-selective NSAIDs (P < 0.001), but 
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not with selective NSAIDs (P = 0.2). When looking at individual drugs within the NSAID class, 
the significant effect remained when only studies using diclofenac were included (P < 0.001). 
Considering only patients receiving ketorolac, the effect was no longer significant (P = 0.1). The 
effect with celecoxib also remained non-significant (P = 0.2). 
 
 This latest review, demonstrating a significant association between NSAID usage and 
anastomotic leakage, involved the largest total number of patients to date. This was the first 
review to look at not only selective vs. non-selective NSAIDs, but to analyze individual drugs 
within each class. If there truly is an increased risk of anastomotic leakage it may not be uniform 
across all NSAIDs.  Not only were the non-selective NSAIDs the only class found to harbor a 
significant association, but within this class, diclofenac (a non-selective NSAID) was found to 
pose an increased risk while Ketorolac (also a non-selective NSAID) did not. Whether or not this 
is a true medication effect, or secondary to unseen confounding factors (i.e. other differences in 
patient factors or patient care between groups) remains unknown at this time. The question 
regarding NSAID safety following gastrointestinal surgery may be more complicated than first 
perceived. It may be that based on differing pharmacodynamics and bioavailability certain 
NSAIDs may pose an increased risk to patients, while others do not.   
 
Summary		
 
 Systematic reviews and meta-analyses provide a standardized approach to examining the 
medical literature. The goal is to provide a definitive answer to guide clinical practice. The 
current literature however does not provide uniform agreement on the impact of NSAIDs post-
operatively. The first review (performed without meta-analyses) from 2011 describes a potential 
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association between NSAIDs and leaks33, but significant methodological flaws and low 
study/patient numbers limit the applicability of such findings. Two meta-analyses completed in 
2013 and 2014 then went on to find contradictory evidence regarding this topic. The first study 
found no significant relationship between NSAIDs and increased leak risk, yet the second one 
published just one year later did find a significant risk34, 36. 
 
Currently no consensus exists regarding the safety of NSAIDs post-operatively. NSAIDs 
are a class of medication with many benefits over opioid medications, and the risk profile has yet 
to be clearly elucidated. Contradictory evidence exists not only regarding the safety of these 
medications, but regarding the risk of individual medications within the NSAID class. 
Furthermore, when looking at the research that has been done on rats (See Section on Animal 
Studies), one can see that there is a clear location dependent effect that NSAIDs have on the 
gastrointestinal tract. The small bowel appears to be affected to a far greater extent by post-
operative NSAIDs than the distal colon, and any study looking to elucidate the effect of NSAIDs 
following colorectal surgery must take this into account. The three previous reviews done on this 
topic have included both small and large bowel anastomoses, and tabulated this as an overall 
effect on anastomotic healing. Any systematic review that aims to assess the risk of NSAIDs 
specifically on colorectal anastomoses must isolate only those studies that involve the colon and 
exclude those that involved small bowel to small bowel anastomoses. 
 
2.3	–	Drug	Specific	Risk	of	Anastomotic	Leak	
 
Introduction	
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 As a greater emphasis is being placed on elucidating the safety profile of NSAIDs we are 
beginning to gain a greater appreciation for the variability that exists within the NSAID class. 
Differing inhibitory and bioavailability profiles lead to different local and systemic effects.  
 
As discussed in the Background section, NSAIDs can be classified as COX-2 selective or 
non-selective inhibitors. However, this classification is an oversimplification of a very complex 
pharmacodynamic picture. Non-selective NSAIDs are thought to indiscriminately inhibit both 
COX-1 and COX-2 enzymes. However, different non-selective NSAIDs have differing affinities 
for the COX-1 and COX-2 enzymes38. Diclofenac, which is categorized as a nonselective 
NSAID, preferentially inhibits COX-2 and behaves very much like a selective NSAID39. On the 
other hand, ketorolac, another nonselective NSAID, has significant preferential inhibition of 
COX-1 over COX-2 and displays a very different risk and safety profile from that of 
diclofenac39. 
 
Often times different drugs within a class are viewed as being essentially 
interchangeable, with a physician’s preference often relating more-so to their previous 
experience and comfort with the medication, rather than evidence-based justification of one drug 
over another. However, analysis of different NSAIDs (diclofenac and ketorolac being the most 
commonly studied), may reveal that broad generalization of safety between drugs even within 
the same sub-class is inappropriate, and the real question that should be asked is not “Do 
NSAIDs pose an increased risk for anastomotic leakage?”, but rather “Are there specific classes 
or medications within the broader NSAID group that are associated with an increased risk of 
anastomotic leakage?”. 
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Literature	Review	
 
Klein	M	et	al.,	20127	
 
 Cohort study looking at a prospectively collected Danish database of 2,756 patients who 
underwent surgery for colorectal cancer, and received a colonic or rectal anastomosis. Treatment 
group consisted of 885 patients who received an NSAID for at least two days’ duration within 
the first seven days after surgery. Ibuprofen was administered to 655 (74%), diclofenac to 226 
(26%). The remaining 1,871 patients who did not receive an NSAID, or received an NSAID for 
less than two days’ duration, served as controls. 
 
 The proportion of patients with anastomotic leakage was significantly higher in the 
NSAID groups than in the control group. Anastomotic leakage occurred in 12.8% of patients 
treated with diclofenac, 8.2% treated with ibuprofen, and in 5.1% of controls (P<0.001 for 
diclofenac vs. controls; P=0.004 for ibuprofen vs. controls). After unadjusted analyses when 
compared with controls, the absolute risk of anastomotic leakage was increased by 7.8% after 
diclofenac treatment and 3.2% after ibuprofen treatment. After the final multivariate logistic 
regression was performed however, only a significant association with diclofenac remained 
(P<0.001), and ibuprofen was no longer associated with an increased risk of post-operative 
anastomotic leak (P = 0.2). There was no significant difference in 30-day postoperative mortality 
between the three groups. 
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Within the control group there were 231 patients who received an NSAID for less than 
two days’ duration. When this subgroup was compared to the remaining controls who did not 
receive an NSAID at all, no difference was found in the proportion of anastomotic leakage 
between the two groups.  
 
The take-away message was that following colorectal cancer resection, there exists an 
increased risk of anastomotic leakage with postoperative diclofenac treatment but not ibuprofen 
treatment. The authors hypothesize that COX-2 inhibition causes micro-thromboses or micro-
emboli that then impairs the anastomotic blood supply, leading to anastomotic leakage. This 
hypothesis is based on research done on patients following coronary artery bypass grafting, 
where the incidence of postoperative thrombotic cardiovascular events increased greatly with 
COX-2 inhibitor treatment40. Also, it has been shown that there exists a lower risk of 
thromboembolic events with ibuprofen and other non-selective drugs41, and this could explain 
why only diclofenac (a non-selective NSAID with very high COX-2 inhibition) and not 
ibuprofen (primarily COX-1 inhibition) increased the risk of anastomotic leakage in this study. 
 
 
Saleh	F	et	al.,	201411	
 
 Retrospective review performed on patients who underwent elective colorectal surgery. 
Aimed at assessing the association between leak rate and ketorolac use within the first 5 post-
operative days. Total of 731 patients identified as having a resection with primary anastomosis 
included in the study. Control group comprised of 376 patients who did not receive an NSAID. 
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Treatment group included a total of 355 patients who received ketorolac within 5 days after 
surgery. The primary outcome of interest was leakage after primary anastomosis. A secondary 
outcome of interest was whether the total ketorolac dose received was associated with an 
increase in anastomotic leak rate. 
 
 There were a total of 24 leaks (3.3 %) in the study population, with 12 leaks in both the 
no ketorolac (3.2 %) and ketorolac (3.4 %) groups (P = 0.886). Subgroup analysis was performed 
using patients in the ketorolac group to assess if a dose-dependent relationship existed between 
ketorolac use and anastomotic leakage. This time a significant association between dose and leak 
rate was found, indicating that higher doses of ketorolac post-operatively may be associated with 
higher leak rates. 
 
 This study suggests that ketorolac appears to be safe when given post-operatively after 
colorectal surgery. However, in subgroup analysis it was suggested that leakage may be more 
likely with higher total doses of ketorolac. As discussed in this paper, the authors cite differences 
in ketorolac’s inhibitory profile as a likely explanation for why no association was found 
between ketorolac and anastomotic leakage. Ketorolac has been found to be up to 1,000 times 
more selective for the COX-1 enzyme compared to COX-242, and this may explain why unlike 
other NSAIDs that inhibit COX-2 to a greater extent ketorolac appears to be safe following 
colorectal surgery. The significant dose-dependent association discussed in this study however 
suggests that at higher doses ketorolac causes COX-2 inhibition at a level sufficient to pose a 
significant risk to patients. Further research would be needed to prove this hypothesis. 
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Subendran	J	et	al.,	20146	
 
 Matched nested case-control study using a prospectively collected database. Cases were 
defined as those who had an anastomotic leak postoperatively. Controls were chosen using 1:1 
matching with cases based on underlying disease, type of surgery, age (within 5 years), sex, and 
year of surgery (within 5 years). The primary and secondary exposure variables were, 
respectively, use of any NSAID and use of ketorolac specifically. A total of 270 patients (135 
case-control pairs) were included in the study. Four pairs were excluded because the anastomotic 
leak occurred more than 12 months after the initial surgery. 
 
 In adjusted analysis, use of any NSAID was associated with a non-significant increase in 
leaks (P = 0.06), while use of ketorolac was associated with a significantly higher risk of 
anastomotic leaks (P = 0.02). There was no significant association between cumulative ketorolac 
dose and anastomotic leakage (P = 0.7). There was no significant association between 
anastomotic leakage and the number of days of NSAID (P = 0.2) or ketorolac use (P = 0.97). 
 
 This study did not find a significant increase in anastomotic leakage with the use of 
postoperative NSAIDs overall, but there was a significant increase in anastomotic leaks with the 
use of ketorolac specifically. These findings are contradictory to those found by Saleh et al. in 
201411, which found ketorolac not to be associated with an increased risk of anastomotic leakage. 
The aforementioned study did however find a dose-dependent relationship between ketorolac 
and post-operative leakage, which this study, despite finding an overall increased risk of leak 
with ketorolac, did not find. Furthermore, both studies looked at data that occurred around the 
same time, from the same city – Toronto (albeit in different hospitals). These conflicting findings 
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underlie the confusion regarding the safety of NSAIDs as a whole post-operatively. They do 
however underlie the principle that there may very well be a drug dependent effect within the 
NSAID class, and further research is needed to clarify this effect. 
 
Bakker	N	et	al.,	20168	
 
 Retrospective database review of 856 patients who underwent an elective colon or rectal 
resection with a primary anastomosis . There were 732 patients with colon cancer, 282 (38.5%) 
of whom did not receive an NSAID, 288 (39.3%) received diclofenac, 93 (12.7%) received 
nabumetone, and 69 patients (9.4%) received ibuprofen. There were also 124 patients with rectal 
cancer, 40 (32%) of whom did not receive an NSAID and 84 (68%) who received diclofenac. 
The primary outcome measured was the incidence of anastomotic leakage. 
 
 Overall, patients receiving NSAIDs had a higher anastomotic leak rate compared to 
patients who did not (P = 0.038). In the colon cancer group, there was a significantly higher leak 
rate in the diclofenac group (11.8%) compared to the group receiving no NSAIDs (6.0%), the 
nabumetone group (1.1%), and the ibuprofen group (4.3%) (P = 0.002). In the rectal cancer 
group there were no leaks in the no NSAIDs group, and 11 patients (13.1%) with an anastomotic 
leak in the diclofenac group (p = 0.017). There was no significant relationship between the post-
operative day that diclofenac was started and the leak rate. There was also no significant 
relationship between the duration of diclofenac use within the first five postoperative days and 
the leak rate. 
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 This study found that diclofenac was an independent risk factor for anastomotic leakage, 
while the other NSAIDs that were used, nabumetone and ibuprofen, did not increase the risk. Of 
note, nabumetone is an NSAID with preferential COX-2 inhibition, similar to diclofenac, yet 
unlike diclofenac it was not associated with an increased leak rate. The theory that COX-2 
inhibition on its own is what causes leakage is an obvious over-simplification. There does 
however seem to be an increasingly large pool of data indicating that diclofenac is not safe for 
use following colorectal surgery.  
 
Summary	
 To answer the ultimate question regarding NSAID safety, it appears that one must be 
aware that there is no single answer. Up until now all attention has been placed on answering the 
question, “Do NSAIDs impair anastomotic healing?”, but the results of such an inquiry have 
been conflicting to say the least. Looking critically through the available literature, there seems 
to be a real indication that some NSAIDs pose a real risk after surgery, but others do not. 
Diclofenac in particular has been found repeatedly to be associated with an increased post-
operative anastomotic leak rate, while the COX-1 preferential inhibitor, ibuprofen, has not. 
 
 But the issue is not simply one of COX-1 vs COX-2 inhibition, otherwise one would 
expect all COX-2 selective inhibitors to be associated with an increased leak risk. For example, 
in 2016 Bakker et al.8 looked at both diclofenac and nabumetone, two drugs with very high 
COX-2 inhibitory profiles. If the issue was simply one of COX-2 inhibition one would expect 
both drugs to be associated with an increased leak rate, however this was not the case. Only 
diclofenac demonstrated an increased risk when given post-operatively, nabumetone did not. 
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Furthermore, in 2014 Subendran et al.6 looked at just ketorolac, an NSAID with a much higher 
COX-1 inhibitory profile than COX-2, and assessed its association with post-operative 
anastomotic leakage. Their findings, that ketorolac is significantly associated with an increased 
leak risk, would go against any hypothesis that this is simply a COX-2 inhibitory effect.  
 
 The take away message is that the question regarding NSAID safety is much more 
complicated than once believed. At this point, where no conclusive recommendation exists 
regarding post-operative NSAID use, if it’s believed a risk exists it may be best to recommend 
against their use as an entire class. It will take much longer to identify which drugs within the 
class are proven safe and which are proven dangerous, and given the push towards non-opioid 
analgesia from initiatives such as the ERAS movement, a safe first step may be to caution 
against their use as a whole. In the long-run though there needs to be an appreciation that this 
may in-fact be a drug-specific effect, and as research into individual drugs becomes available, 
the recommendations regarding their use can be further refined. 
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Chapter	3	–	Methods	
 
3.1	–	PRISMA	Statement	
 
 The following systematic review and meta-analysis was completed using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines43. These 
guidelines were developed in 2005 following a three-day meeting designed to expand upon the 
existing QUOROM (Quality of Reporting of Meta-Analysis) Statement. The rationale behind the 
PRISMA statement has been to ensure the transparency and completeness in the reporting of 
systematic reviews and meta-analyses, and as such those guidelines have been used in the design 
of this study. An up-to-date checklist using the current PRISMA guidelines can be found in 
Appendix 3.   
 
3.2	–	Protocol		
 
 Prior to study commencement a research protocol was created as part of an initial 
research abstract outlining the process by which data sources would be obtained, the outcomes of 
interest to be assessed, and the means by which data would be compiled and analyzed. This 
protocol was agreed upon by all members of the research team and forwarded along to the 
Memorial University Clinical Epidemiology program for approval. The methodology outlined in 
that initial protocol was followed throughout study completion and will be outlined in the 
following sections.  
 
 
 
35		
	
3.3	–	PICO	
 Patients:          Patients undergoing colorectal resection and primary anastomosis 
 Intervention:   Administration of an NSAID post-operatively (within the first 7 days) 
 Control:           Patients who haven’t received an NSAID post-operatively (first 7 days) 
 Outcomes:       Primary outcome - Post-operative anastomotic leak rate 
         Sub-group analysis - Selective vs non-selective NSAIDs, ketorolac vs             
         diclofenac 
 
3.4	–	Eligibility	Criteria	
 Randomized control trials, cohort studies, and case-control studies performed on humans 
undergoing a colonic or rectal resection with a primary anastomosis were eligible. As there is 
currently very limited research available looking at this topic, a decision was made to use both 
randomized control trials and non-randomized observational studies. Given that the pooling of 
crude events from non-randomized studies may be misleading as they do not take into account 
confounding factors, a decision was made to use multivariate adjusted risk estimates from the 
observational data whenever possible.  
 
Colonic anastomoses were defined as any anastomosis in which at least one limb 
involved colonic tissue (i.e. ileocolic anastomoses involving small bowel and colon were 
classified as a colonic anastomosis). Similarly, rectal anastomoses were defined as an 
anastomosis whereby at least one limb included rectal tissue (i.e. colorectal anastomosis 
following proximal rectal resection). No restriction was placed on publication date or language. 
Included trials were required to involve patients who received a primary colonic or rectal 
anastomosis and post-operative NSAID analgesia within 7 days of surgery, as well as a control 
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group of patients undergoing a similar surgery who did not receive NSAIDs (could have received 
a placebo or any other form of non-NSAID analgesia). Studies were required to have assessed 
anastomotic leakage as a primary outcome. 
 
 Studies were excluded if they were animal based, did not involve a colonic or rectal 
anastomosis, were editorials or case reports, did not look at anastomotic leak rates as a primary 
outcome, or involved an additional intervention in addition to NSAID analgesia in the treatment 
arm (i.e. NSAIDs plus steroids vs placebo). Studies that included small-bowel anastomoses were 
not included. This decision was made primarily based on animal studies that have demonstrated 
a location-dependant effect of NSAIDs on the gastrointestinal tract (See Literature Review). It’s 
been shown that the small bowel is affected by non-steroidal anti-inflammatories to a greater 
extent than the distal colon26, 29, 31, therefore it was decided that to accurately assess the effect of 
NSAIDs on colonic and rectal anastomoses studies that included small bowel anastomoses 
needed to be excluded.  
 
3.5	–  Information	Sources	
 
 Studies were identified by searching electronic databases and scanning reference lists of 
articles. No limits were placed on language. It was decided that if foreign papers were identified 
they would be translated and included in the article review. The databases searched included 
MEDLINE, EMBASE, and CINAHL. The final search was completed on November 24, 2016. 
 
 The MEDLINE database was selected as it is generally regarded to be one of the most 
comprehensive sources of health care related research in the world. The EMBASE database 
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covers much of the same subject matter as the MEDLINE database, but provides an additional 
focus on drugs and pharmacology. Given the focus of this study on NSAID medications the 
EMBASE database was deemed to be an important source of research information. Lastly, to 
ensure that we performed a well rounded and complete literature search we also included the 
CINAHL database in our search. CINAHL is generally regarded as a very clinically oriented 
database with a focus on nursing and allied health disciplines. 
 
3.6	–	Search	
 
 Given the narrow scope of this research question and the limited number of studies 
available, a broad search strategy was employed to ensure that any and all relevant articles were 
assessed. The following two search terms were used with all 3 databases: “anastomosis” and 
“NSAIDs”. Given that the search term “NSAIDs” is synonymous with the term “non-steroidal 
anti-inflammatory” and the singular form – “NSAID”, these three terms were grouped together 
using the “OR” function. As an example, our MEDLINE database search consisted of the 
following inquiry: “Anastomosis AND (NSAID OR NSAIDs OR non-steroidal anti-
inflammatory)”. The same strategy was employed for the EMBASE and CINAHL database 
searches. 
 
3.7	–	Study	Selection	
 
  Study eligibility was evaluated in an un-blinded standardized manner by two 
independent physicians affiliated with Memorial University. Any disagreements between 
reviewers was to be resolved by consensus. Initial screening was performed by analysis of article 
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titles/abstracts. Articles were then read in full to assess for final inclusion/exclusion into the 
systematic review and meta-analysis. 
 
3.8	–	Data	Collection	Process 
Data was extracted independently by one author, with independent verification by a 
second physician/researcher. Data was input manually into the Review Manager (Rev-Man) 5.3 
software system. Discrepancies were to be resolved with a discussion between the two 
independent researchers. If consensus could not be reached a third independent researcher would 
decide. 	
 
3.9	–	Data	Items	
 
Extracted data from each study included: (1) study design and study inclusion/exclusion 
criteria; (2) type of intervention (including type of NSAID, duration, and frequency of use); (3) 
type of outcome measured, including the definition used for diagnosing an anastomotic leak; and 
(4) individual anastomotic leak rates from the intervention and control groups in each study.  
 
3.10	–	Risk	of	Bias	in	Individual	Studies	
 
 Due to the nature of the question being examined, all studies were of a non-randomized, 
retrospective nature. As per Cochrane guidelines a risk of bias assessment was performed using 
the Risk of Bias in Non-Randomized Studies of Interventions (ROBINS-I) tool2. Studies were 
graded on risk of bias to due confounding, selection of participants, classification of 
interventions, deviations from intended interventions, missing data, measurement of outcomes, 
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and selection of the reported units. A final overall risk of bias was then determined. Overall risk 
of bias was placed into one of five categories3: 
 1: Low Risk of Bias – the study is comparable to a well performed RCT 
 
2: Medium Risk of Bias – the study provides sound evidence for an RCT, but cannot be  
 considered comparable to a well performed RCT 
  
3: Serious Risk of Bias – the study has some important problems 
  
4: Critical Risk of Bias – the study is too problematic to provide any useful evidence and  
 should not be included in any synthesis 
  
5: No Information on which to base a judgment about risk 
 
3.11	–	Summary	Measures	
 
 Meta-analysis was to be performed by computing the odds ratio (OR) from the original 
data using the Cochran-Mantel–Haenszel method (with a 95% confidence interval). An odds 
ratio greater than 1 was indicative of an increased risk of anastomotic leakage in the group 
administered NSAIDs.  A P-value of 0.05 was considered significant for all analyses. The 
primary outcome measure was the incidence of anastomotic leakage following surgery in each 
group. 
 
The Cochran-Mantel–Haenszel test (also known as the Mantel-Haenszel test) is used to 
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assess the association between a binary intervention/exposure (such as NSAID exposure and no 
NSAID exposure), and a binary/dichotomous outcome (such as the presence of an anastomotic 
leak and the absence of a leak). The Mantel-Haenszel test provides an estimate of the common 
odds ratio, and tests whether the overall degree of association between the exposure and the 
outcome is significant. 
 
Although it is theorized by some that the relative risk is an easier outcome to interpret 
clinically, and that misinterpretation of the odds ratio can lead to over/under estimation of the 
risk associated with an exposure45, our decision to include case-control studies as part of the 
analysis precludes the use of relative risk as the principle summary measure. Both odds ratio and 
relative risk are summary measures that can be used for dichotomous outcomes. 
 
3.12	–	Synthesis	of	Results	
 
Synthesis and graphical representation of the meta-analysis was to be performed with the 
Review Manager (Rev-Man) 5.3 software, using a random-effects model. A forest plot would be 
created to display the results of each study as well as the overall result. Inter-study heterogeneity 
would then be assessed using the I2 statistic.  
 
The I2 statistic describes the percentage of variation across studies that is due to 
heterogeneity rather than by chance alone44. In comparison to the chi-squared test (another test of 
heterogeneity), the I2 statistic is far more reliable in meta-analyses involving smaller numbers of 
studies. When the number of studies is low, the chi-squared value becomes underpowered 
making interpretation of a non-significant value very difficult. Given the focused nature of our 
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clinical question, and presumed low number of available studies, it was believed that the I2 
statistic would be a more reliable measure of heterogeneity.  
 
Along with the I2 statistic, it was also determined that a random-effects model would be 
used instead of a fixed-effects model. The fixed-effects model works under the assumption that 
the true effect size for all studies in a meta-analysis are identical, and that any variation seen is 
due to sampling error. Meanwhile the random-effects model assumes that the true effect size 
varies from one study to another, and that the selected studies represent a random sample of 
possible effect sizes that could have been observed. As such, in the fixed-effects model smaller 
studies are given a very small weight, while in the random-effects model smaller studies are 
given a comparatively larger weight as it is believed that each study provides unique information 
about a different effect size. 
 
  In our study we chose a random-effects model from the start. Based on our review of the 
existing literature (see Literature Review), we believed that the effect size for each study would 
vary based on the intrinsic differences observed in each study. Across studies there were 
significant differences ranging from which NSAIDs were being administered, their duration and 
timing, the type of anastomosis created, to the diagnostic criteria used to identify post-operative 
leaks. Because of these differences, it was believed that each study would have its own unique 
true effect size and that a fixed-effects model would be inappropriate. 
 
3.13	–	Risk	of	Bias	Across	Studies	
 
 Publication bias was assessed via a graphical representation of precision vs effect 
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estimate (i.e. a funnel plot). This graphical representation plots the effect estimates from 
individual studies (in the form of an odds ratio), against the inverse standard error of the 
aforementioned studies. The underlying principle of such as plot being that the effect estimates 
from less precise studies (higher standard error) will scatter more widely at the bottom of the 
graph, with the spread narrowing among the more precise (lower standard error) studies. In the 
absence of bias, the plot should resemble a symmetrical inverted funnel. 
 
 Heterogeneity, reporting bias, and chance may all lead to asymmetry or other shapes in 
funnel plots46. Reporting bias arises when the publication of research findings is influenced by 
the nature of the results. Statistically significant “positive” results are more likely to be 
published, published rapidly, published in English, published more than once, published in high 
impact journals, and cited by others. Data that would lead to negative results may be filtered, 
manipulated, or presented in such a way that they become positive. These biases would cause an 
asymmetry if, for example, studies that indicate that NSAIDs increase the leak rate are more 
likely to published than studies that show no effect, or vice-versa. 
 
3.14	–	Additional	Analysis	
 
 Further sub-group analysis was planned based on the findings from our literature review. 
Given the hypothesis that there may be a drug specific effect that NSAIDs have on the healing of 
colorectal anastomoses (see Literature Review), further sub-group analysis was planned to 
stratify patients based on the type of NSAID they received (selective vs non-selective). We then 
aimed to further investigate this drug specific effect by looking at different medications within a 
single class. Ketorolac and diclofenac are two medications that have been studied in great detail, 
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and both belong to the non-selective NSAID class. We aimed to look at the drug specific effect 
of each medication versus placebo and see if there were significant differences. In doing so, we 
planned to answer the following questions:  
A) Are NSAIDs as a whole associated with an increased risk of anastomotic leakage?  
B) If so, is this effect isolated to one class of NSAIDs? 
C) And if so, is this effect uniform across different medications within the same class? 
Chapter	4	–	Results	
4.1	–	Study	Selection	
 
 A search of MEDLINE, EMBASE, and CINHAL yielded a total of 432 articles. After 
adjusting for duplicates we were left with a total of 373 non-duplicate articles (see Figure 4.1 for 
PRISMA diagram). These 373 articles were then screened and we were then left with 31 articles 
remaining for full-text review. Of these remaining articles 24 were excluded because they did not 
meet our inclusion/exclusion criteria. Seven articles were experimental rat studies, 6 were review 
papers or author replies, 6 looked at comparison groups that did not meet inclusion/exclusion 
criteria (i.e. one NSAID vs. another, or an NSAID plus another intervention vs placebo) or 
primary outcomes that did not meet inclusion/exclusion criteria (i.e. length of hospital stay), 1 
was a poster abstract that did not meet inclusion criteria, 1 was a project proposal, 1 included 
bariatric surgery patients in their patient pool, and 2 were previously completed meta-analyses. 
Seven articles remained which met our inclusion/exclusion criteria and were included in the 
systematic review. We then went on to check the reference lists of relevant papers that were both 
included and not included in our analysis for articles we may have missed in our initial 
screening. No articles that we had not previously screened were found.  
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Figure	4.1:		PRISMA	Diagram	
 
4.2	–	Study	Characteristics	
 
 In total 9,835 participants were involved in the 7 selected studies. All studies were 
published in English with 3 originating from North America (Canada and the United States), and 
4 from Europe (Denmark and the Netherlands). Three were single-centered studies and 4 were 
multi-centered. With respect to their study methodology, 6 of the selected studies were of a 
retrospective cohort design, while one (Subendran 2014) was a nested, matched case-control 
study (See Tables 1 – 7 for full study details).  
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The main inclusion criteria in all studies involved adults undergoing colonic or rectal 
resection, who received a primary anastomosis and then an NSAID within 7 days following 
surgery. No other gastro-intestinal anastomosis was included in any of the 7 studies. The 
NSAIDs given in 5 of the studies were only non-selective NSAIDs, 1 study looked at both 
selective and non-selective NSAIDs, and 1 did not specify which type of NSAID was used. Of 
the 6 studies that specified the exact NSAID given, 4 involved diclofenac and 2 involved 
ketorolac. 
 
The primary outcome of interest in all 7 studies was post-operative anastomotic leak. In 5 
studies an anastomotic leak was confirmed whenever signs of leakage were present on imaging 
or subsequent surgery. In the other 3 studies a leak was considered present only when it was 
confirmed at re-operation. Six of the 7 studies included secondary outcome analysis in their 
paper, however the secondary outcomes were quite varied across studies. 
 
4.3	–	Risk	of	Bias	Within	Studies	
 
 The risk of bias assessment was completed using the ROBINS-I tool (see Appendix 4 – 
10). All studies were graded using the official ROBINS-I scoring guidelines3. Four studies were 
deemed Moderate Risk based on baseline differences in potential confounding variables between 
the control and intervention groups. Interestingly, in three of those four studies (Bakker et al. 
20068, Klein et al. 200910, and Saleh et al. 201411) patients in the control group began with 
poorer baseline health, while in the end it was the NSAID group that was found to have a 
significantly higher leak rate.  
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The other 3 studies were deemed Serious Risk. Paulasir et al., 20155 was deemed Serious 
Risk as the authors did not classify and account for rectal vs colonic anastomosis – a potential 
confounding factor given previous literature indicating a location specific effect that NSAIDs 
exhibit throughout the gastrointestinal tract (see Literature Review). Subendran et al., 20146 was 
classified as Serious Risk because the authors did not take into account pre-existing co-
morbidities in their analysis. Pre-existing comorbidities play a major role in risk stratification of 
patients for post-operative anastomotic leak, and without documentation of what if any 
differences existed between groups, one cannot be sure if the results found within this study were 
secondary to the intervention in question (NSAIDs), or to unknown differences in baseline health 
amongst patients. Similarly, Klein et al., 20127 was classified as being at Serious Risk of bias 
because of a failure to assess whether or not patients received a protective stoma in their 
analysis. Patients with a protective stoma are at lower risk of clinically apparent anastomotic 
leakage, and as such differences between groups in protective stoma formation must be taken 
into account. 
	
4.4	–	Results	of	Individual	Studies/Synthesis	of	Results	
 
Overall	NSAID	Use	and	Anastomotic	Leak	Rate	
 
 The anastomotic leak rate in each study for both intervention and control groups is listed 
in Figure 4.2. NSAIDs were associated with a significantly higher anastomotic leak rate in 4 of 
the 7 studies, with an overall leak rate of 300/3555 (8.44%) compared to 302/6280 (4.81%). 
When synthesized using our pre-ordained parameters (M-H analysis, OR with random-effects 
model) the overall anastomotic leak rate was found to be significantly higher in the NSAID 
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group [OR 1.58 (1.23, 2.03), P = 0.0003]. Heterogeneity as defined by our I2 statistics was 
classified as moderate (38%). 
 
 
Figure	4.2:	NSAIDs	post	colorectal	surgery	and	anastomotic	leak	rate	
 
 
Class	Specific	Anastomotic	Leak	Rate	
 
 Of the 7 included studies, documentation of NSAID type was provided by 6 (the 
exception being Paulasir et al., 20155). All 6 studies included non-selective NSAIDs in their 
intervention group, while 1 (Gorrisen et al., 20129) included both selective (celecoxib and 
meloxicam) and non-selective NSAIDs.  
 
When looked at in isolation, Gorrisen et al., 20129 found an increased anastomotic leak 
rate with non-selective NSAIDs compared to selective NSAIDs [OR 2.13 (1.24, 3.65); P = 
0.006]. Selective COX-2 inhibitors were not associated with an increased risk of anastomotic 
leak when compared to controls [OR 1.17 (0.50, 2.74), P = 0.7].  
 
Comparison: NSAIDs versus No NSAIDs post colorectal surgery 
Outcome: Anastomotic leak 
NSAIDS	Decrease	AL	Rate						NSAIDS	Increase	AL	Rate	
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We then isolated patients from the 6 studies who took only non-selective NSAIDs and 
compared them to the controls in each study. Of this patient group, a significantly elevated 
anastomotic leak rate was found in 4 of the 6 studies (Figure 4.3). The overall leak rate in the 
non-selective NSAID group was found to be 248/2310 (11.64%), compared to 240/3499 (6.86%) 
in the control group (OR 1.77 [1.43, 2.20], P < 0.00001). Heterogeneity between groups was low 
(I2 = 8%).     
  
	
Figure	4.3:	Non-selective	NSAIDs	post	colorectal	surgery	and	anastomotic	leak	rate	
	
	
Drug	Specific	Anastomotic	Leak	Rate	
 
 Used by patients in 4 of the 6 studies with drug-specific documentation, diclofenac was 
the most commonly used medication across studies. The second most commonly used 
medication was ketorolac (present in 2 of 6 studies). Both medications are classified as non-
selective NSAIDs, and a drug-specific analysis was done to assess for heterogeneity within the 
non-selective class with regards to risk profiles.  
 
Of the 4 studies in which diclofenac was said to have been used, 3 provided isolated 
Comparison: Non-selective NSAIDs versus No NSAIDs post colorectal surgery 
Outcome: Anastomotic leak 
Non-selective	NSAIDS		 																					Non-Selective	NSAIDS		
Decrease	AL	Rate					 																					Increase	AL	Rate	
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anastomotic leak rates for patients taking diclofenac (Figure 4.4).  In all 3 studies, diclofenac was 
associated with a statistically significant increased anastomotic leak rate [OR 2.74 (1.94, 3.88), P 
< 0.00001]. The overall leak rate in patients taking diclofenac across these studies was 81/631 
(12.84%) compared to 113/2235 (5.06%) in controls. The one study that did not include specific 
numbers for diclofenac (Gorrisen et al., 20129), did however indicate that diclofenac was the 
most commonly used non-selective NSAID amongst their study population, and non-selective 
NSAIDs as a class were found to be associated with a significantly increased post-operative leak 
rate [14.5% leak rate; OR 2.13 (1.24, 3.65); P = 0.006]. Ketorolac specific leak rates were 
documented in two studies (Figure 4.5), with neither finding ketorolac to be associated with a 
significant change in the post-operative leak rate [OR 1.36 (0.89, 2.06), P = 0.16]. Heterogeneity 
was absent (I2 = 0%) in both the diclofenac and ketorolac sub-group analyses. 
 
 
 
Figure	4.4:	Diclofenac	post	colorectal	surgery	and	anastomotic	leak	rate	
 
 
 
Comparison: Diclofenac versus No NSAIDs post colorectal surgery 
Outcome: Anastomotic leak 
Diclofenac	Decreases	AL	Rate					 Diclofenac	Increases	AL	Rate	
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Figure	4.5:	Ketorolac	post	colorectal	surgery	and	anastomotic	leak	rate	
 
4.5	–	Risk	of	Bias	Across	Studies	
 
 Moderate heterogeneity was found in the overall NSAID vs control group analysis (I2 = 
38%). This heterogeneity was further assessed using a funnel plot (Figure 4.6). Given the 
relatively low number of studies included in this analysis the general shape of our funnel plot 
remained fairly symmetrical. When looking at the forest plot one study stands out, that being the 
least precise study at the base of the pyramid (Klein et al., 200910). As expected, the least precise 
study demonstrates a size effect farthest from the mean. The studies with the highest precision all 
clustered very closely to the mean at the top of our plot, and the study with the lowest precision 
was positioned farthest from the mean at the base of our plot. While the left side of the base 
remains bare in this plot (which would represent studies that showed a protective effect with 
NSAIDs), this is likely to be secondary to the low number of studies included, rather than an 
inherent bias. As such there is no indication from our funnel plot that there is a significant risk of 
bias present across studies 
 
 
Comparison: Ketorolac versus No NSAIDs post colorectal surgery 
Outcome: Anastomotic leak 
Ketorolac	Decreases	AL	Rate					 Ketorolac	Increases	AL	Rate	
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Figure	4.6:	Funnel	plot	(NSAID	use	vs	No	NSAID	use)	
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Chapter	5	–	Discussion	
 
 Overall, the evidence in this study indicates that non-selective NSAIDs are associated 
with an increased risk of anastomotic leakage following colorectal surgery. When grouped 
together as an entire class, NSAIDs in our study were found to significantly increase the leak rate 
of colonic and rectal anastomoses. With further sub-group analysis however this effect was not 
found to be consistent across all NSAIDs, with medications within the same class demonstrated 
conflicting risk profiles.  
 
 This meta-analysis is the first to look at isolated colonic and rectal anastomotic leak rates, 
as well as the first to perform drug-specific analysis on the effect of certain NSAIDs on 
anastomotic healing. As demonstrated in several animal studies, the effect that NSAIDs have on 
anastomotic healing varies based on the location within the gastrointestinal tract26, 29, 31. Small 
bowel anastomoses have been shown to be affected by post-operative NSAID use to a greater 
extent than distal colonic anastomoses. Previous meta-analysis performed to assess the impact of 
NSAIDs on anastomotic healing have failed to take into account this potential location 
dependent effect that NSAIDs have on the gastrointestinal tract33, 34, 36.  
 
 While this study has taken a first step towards stratifying the impact that NSAIDs have 
based on anastomotic location, there are still significant limitations present. In our study we 
grouped all colonic and rectal anastomoses as one category. Research in 2013 from van der 
Vijver et al.29 however indicated that the different segments of the colon may have be a variable 
response to NSAIDs, and that proximal colonic anastomoses may demonstrate a risk profile 
analogous to that of small bowel anastomoses, while distal colonic anastomoses are affected to a 
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far lesser degree and do not demonstrate the same risk profile. 
 
 In our study we did not analyze patients based on proximal or distal colonic anastomoses, 
nor did we stratify them based on colonic versus rectal anastomoses. This was in large part due 
to fact that the studies that have been published looking at colorectal anastomoses and NSAID 
use do not differentiate between the proximal and distal colon in their analysis. As such we could 
not obtain the data needed to perform a sub-group analysis such as this. Six of the seven studies 
we included in our analysis did include anastomotic location within their demographic 
information, which was used to assess for baseline differences in confounding variables between 
groups. None of those studies went on to use that information to perform sub-group data analysis 
based on anastomotic type though (i.e. ileocolic anastomotic leak rate, recto-sigmoid anastomotic 
leak rate, etc.). Given the current literature indicating that NSAIDs affect not only the 
gastrointestinal tract to different degrees based on location, but also different segments of the 
colon based on location, future research should look to either isolate their patients to only one 
type of anastomosis (i.e. ileocolic anastomoses following right hemi-colectomy), or to provide 
stratified data based on anastomotic location. 
 
 As to why NSAIDs impair anastomotic healing and why different segments of the 
gastrointestinal tract are affected differently, the pathophysiological mechanism still remains up 
for debate. Histological factors associated with the healing process certainly seem to be affected 
following NSAID use. These medications appear to decrease fibroblast infiltration, decrease 
granulation tissue formation, decrease re-epithelialization, and increase microscopic necrosis32. 
Taken all together this can certainly lead to impaired wound healing and tissue regeneration. 
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Furthermore, NSAIDs appear to have an effect on collagen deposition and cross-linking, 
although this effect is not yet clear. In 2004 Cahill et al.25 hypothesized that NSAIDs impair 
cross-linkage rather than collagen production, a finding echoed in 2013 by van der Vijver et al.29 
who found no change in collagen concentration within ileal or colonic tissues after NSAID use. 
In a 2012 study by Klein et al.28 however, there was in-fact find a statistically significant 
reduction in collagen in colonic tissue following NSAID administration, contradicting the 
findings from the previous two studies. 
 
 Although it’s unclear what the overall effect is on intestinal collagen structure/function, 
studies have shown that COX-2 expression is greatest in the ileum and that this expression 
decreases after NSAID use29, 30. This has led to theories that the increased leak rate associated 
with NSAIDs may in-fact be a COX-2 specific inhibitory effect. When tested clinically however 
this has not been proven to be the case. In 2014 Bhangu et al.36 performed sub-group analysis in 
their meta-analysis to stratify selective vs. non-selective NSAIDs. They found that only the non-
selective NSAID group was associated with an increased anastomotic leak rate post-operatively, 
while the selective COX-2 inhibitor group did not demonstrate any significant change in leak 
rate. These findings are in-line with our own results, in which we found that when patient data 
was analyzed based on class of NSAID received, only the non-selective NSAID group 
demonstrated an increased risk of anastomotic leakage. 
 
 We then went on to take this analysis one step further and performed an additional sub-
group analysis on individual drugs within the non-selective NSAID class. In our study we found 
the association between post-operative leak rate and medication use inconsistent when two non-
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selective NSAIDs, ketorolac and diclofenac, were compared to controls. While both are 
categorized within the same class of medication, only diclofenac was associated with an 
increased leak rate. This would indicate that the question regarding NSAID safety is much more 
complicated than once believed, and that in the long-run there needs to be an appreciation that 
this may in-fact be a drug-specific effect. 
 
 Nevertheless, there are limitations that must be taken into account when interpreting this 
data. Because we narrowed down our research question to a very focused topic, colorectal 
anastomotic healing following post-operative NSAID use, the number of studies present within 
this meta-analysis is relatively low. This is especially important when considering the sub-group 
analysis that was performed. Only 1 study included selective NSAID medications in their 
published data, and when performing our medication-specific analysis only 3 studies were 
included in the diclofenac group, and 2 in the ketorolac group. The individual results from these 
sub-group analyses (that diclofenac, but not ketorolac or selective NSAIDs were significantly 
associated with an increased leak rate) must be taken with a grain of salt, as further research is 
needed to truly clarify these class and drug-specific risk profiles. The real take-away message is 
that the question regarding NSAID safety is a very complex one that cannot be answered with a 
broad study that generalizes all NSAIDs as one medication with the same risk and safety profile. 
 
Furthermore, another inherent limitation of a review such as this is the reliance on non-
randomized data. Prospective, randomized clinical trials provide the strongest evidence upon 
which recommendations can be made. Within this paper nearly half of the studies examined 
posed potential bias secondary to confounding factors that were unaccounted for by the study 
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authors. Of the remaining studies that measured these confounding factors, to some degree or 
another they all contained baseline differences between intervention and control groups that 
made final size effect interpretations difficult. As with any study reliant on observational data, it 
is difficult to differentiate association with causation. While some studies did show an increased 
leak rate with NSAID usage, there also remains the possibility that those patients with a post-
operative leak required greater pain control in the immediate post-operative setting, necessitating 
the addition of an NSAID to their management plan. Potential confounders such as these 
highlight why a true answer to the question regarding NSAIDs and their safety can’t be made 
until high-quality randomized studies are performed. 
 
Within the context of our study, alternative analytic approaches to decrease the 
confounding inherent in observational studies include instrumental variable analysis and 
propensity score analysis. Instrumental variable analysis, which has primarily been used in the 
context of economic research in the past, relies on the use of a third variable, an “instrumental 
variable”, which correlates with treatment selection (i.e. NSAID use in this study) but not 
directly with the outcome variable (i.e. anastomotic leakage). The instrumental variable creates 
variance to estimate the effect of the treatment on the outcome. The inherent difficulty in using 
this approach is in finding an instrumental variable that correlates strongly with the treatment 
variable while also not having a direct effect on the outcome, other than indirectly through the 
treatment. This often times relies on expert opinion.  The availability of such data in the context 
of many of these observational studies is often times limited as well. Such an analysis is best 
performed when large data sets are available, as is the case in many large scale economic 
analyses.  
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Going forward significant efforts will need to be made to confidently identify which 
individual NSAIDs increase the risk of anastomotic leakage and which don’t. Given the increase 
in non-opioid analgesia in many centers these days, there are now opportunities to develop large, 
prospectively randomized control trials comparing individual NSAIDs to both placebo and each 
other. These studies would minimize many of the inherent biases present in the retrospective 
reviews available today, and allow for individualized assessment of NSAIDs rather than the class 
based studies we currently have. Large prospective studies, such as a theoretical one that 
randomized patients to a diclofenac group, a ketorolac group, and a placebo/traditional opioid 
analgesia group, would ultimately lead to the production of definitive guidelines regarding drug 
safety during anastomotic healing.  
 
5.1	–	Conclusion	
 
 Anastomotic leakage results in significant morbidity and mortality for patients. While 
current ERAS guidelines recommend non-opioid analgesia post-operatively for colorectal 
patients, our findings indicate that the use of NSAIDs in the immediate post-operative period 
(within 7 days) in these patients may increase the risk of a post-operative anastomotic leak. 
 
 Where no conclusive recommendation currently exists regarding post-operative NSAID 
use, we advise great caution when prescribing NSAIDs following colonic or rectal anastomotic 
creation.  While our findings indicate that there may be certain NSAIDs that are safe for post-
operative analgesia, given the large amount of work still needed to properly clarify the individual 
risk profiles of these medications, a safe first step may be to caution against their use entirely. As 
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more data regarding individual NSAIDs becomes available, further refinement of the guidelines 
can be implemented to ensure that these medications are administered only when proven safe.  
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Tables	
 
Table	1	–	Study	Characteristic	Table	(Bakker	et	al.	2006)	
 
Bakker et al. 2006  
Risk of Bias Moderate 
 
Groups dissimilar with respect to baseline confounding variables 
Study Design Retrospective Cohort Study 
Population 856 Patients 
Netherlands 
Single-Center 
 
Inclusion Criteria: Patients undergoing an elective colon or rectal resection with primary anastomosis because 
of malignancy and treated within an enhanced recovery program 
 
Exclusion Criteria: Benign disease, acute operation, colostomy closure, and any form of stoma except for a 
deviating ileostomy in rectal resection with primary anastomosis after preoperative chemo/radiation 
Intervention N = 534 
 
NSAID started on the second postoperative day and continued until oral analgesia could be reduced. Relevant 
dose of NSAID defined as a prescription of more than one consecutive day.  
 
Between 2006 and 2009, ibuprofen was prescribed for patients who were 70 years of age and younger and 
nabumetone was prescribed for patients older than 70 years of age. 
Between 2010 and 2013, the protocol was changed and diclofenac was the NSAID prescribed for all patients 
 
Control N = 322 
No NSAIDs given post-operatively 
Outcome Anastomotic Leak Rate 
 
No time limit given from surgery 
 
Included abscess formation in the quadrant of the anastomosis requiring drainage as an anastomotic leak 
 
Secondary Outcomes: Surgical site infection, fascial 
dehiscence, ileus, pneumonia, urinary tract infection, in-hospital 
mortality 
Results Intervention: 9.2% 
Control: 5.3% 
p<0.05 
Odds Ratio: 1.81 [1.03, 3.21] 
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Table	2	–	Study	Characteristic	Table	(Gorissen	et	al.	2012)	
 
Gorrissen et al. 2012  
Risk of Bias Moderate 
 
Groups dissimilar with respect to baseline confounding variables 
Study Design Retrospective Cohort Study 
Population 795 Patients 
Netherlands 
Multi-Center 
 
Inclusion criteria: Patients undergoing colonic or rectal resection with primary anastomosis between Jan. 2008 
and Dec. 2010 
 
Exclusion criteria: none given 
Intervention N = 324 
 
Any NSAID use within the first 5 days post-operatively 
Control N = 471 
 
No NSAIDs given post-operatively 
Outcome Anastomotic Leak Rate  
 
Defined as clinical and radiological signs of anastomotic leakage as confirmed by re-operation or occurrence of 
an enterocutaneous fistula 
 
Secondary outcome: Complications according to Dindo-Clavien classification system 
 
Results Intervention: 13.2% 
Control: 7.6% 
p<0.05 
Odds Ratio: 
1.85 [1.16, 2.95] 
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Table	3	–	Study	Characteristic	Table	(Klein	et	al.	2009)	
 
Klein et al. 2009  
Risk of Bias Moderate 
 
Groups dissimilar with respect to baseline confounding variables that were measured 
Study Design Retrospective Cohort Study 
Population 75 Patients 
Denmark 
Single-Center 
 
Inclusion criteria: Patients undergoing laparoscopic colorectal resection with primary anastomosis between 
October 2004 and June 2007. All cases done by the same operating team. 
 
Exclusion criteria: none given 
Intervention N = 33 
 
Oral diclofenac (150mg/day) starting POD #1 
 
Control N = 42 
 
No diclofenac given 
Outcome Anastomotic Leak Rate  
 
Defined as clinically significant leakage where re-operation was needed 
Secondary outcomes: None 
Results Intervention: 21.2% 
Control: 2.4% 
p<0.05 
Odds Ratio: 11.04 [1.28, 94.97] 
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Table	4	–	Study	Characteristic	Table	(Klein	et	al.	2012)	
 
Klein et al. 2012  
Risk of Bias Serious 
 
Not all potential confounding variables measured 
 
Groups dissimilar with respect to baseline confounding variables that were measured 
 
4 patients excluded from analysis following commencement of intervention (because took NSAID other than 
ibuprofen/diclofenac) 
 
Participants excluded due to missing data 
Study Design Retrospective Cohort Study 
Population 2,756 Patients 
Denmark 
Multi-Center 
 
Inclusion criteria: Patients with available electronic medical records who had undergone an elective operation 
for colorectal cancer between January 1, 2006 and December 31, 2009 with either colonic or rectal resection, 
and received a primary anastomosis. 
 
Exclusion criteria: none given 
Intervention N = 885 
 
NSAID taken post-operatively (at least two days’ treatment) within the first 7 days, with a relevant daily dose of 
at least 50 mg for diclofenac and at least 800 mg for ibuprofen 
 
Control N = 1,871 
 
No NSAID taken post-operatively 
Outcome Anastomotic Leak Rate  
 
Defined as as clinical leakage requiring acute surgical intervention such as re-laparoscopy or re-laparotomy  
Radiological or endoscopic drainage was not considered surgical intervention 
Secondary Outcome: Mortality within 30 days 
Results Intervention: 9.4% 
Control: 5.1% 
p<0.05 
Odds Ratio: 1.93 [1.42, 2.63] 
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Table	5	–	Study	Characteristic	Table	(Paulasir	et	al.	2015)	
 
Paulasir et al. 2015  
Risk of Bias Serious 
 
Not all potential confounding variables measured. 
 
Groups dissimilar with respect to baseline confounding variables that were measured. 
 
Study Design Retrospective Cohort Study 
Population 4,360 Patients 
United States 
Multi-Center 
 
Inclusion criteria: Non-pregnant patients over the age of 18 who underwent colon and rectal surgery with bowel 
anastomosis between July 2012 through February 2014 
 
Exclusion criteria: Age under 18, current pregnancy, American Society of Anesthesiologists (ASA) class 5 and 
6, the presence of preoperative open wounds with or without infection 
Intervention N = 1,297 
 
NSAID (not specified) taken on post-op day 1 
 
Control N = 3,063 
 
No NSAID taken post-operatively 
Outcome Anastomotic Leak Rate  
 
Defined as as a clinically diagnosed leak at the site of the intestinal anastomosis requiring one or more of the 
following interventions: antibiotic treatment, percutaneous drainage, re-operation with new anastomosis, re-
operation with proximal diversion, or re-operation with end stoma 
 
Secondary outcomes: any surgical site infection, sepsis, death within 30 days of surgery 
 
Results Intervention: 2.9% 
Control: 2.6% 
p>0.05 
Odds Ratio: 1.11 [0.75, 1.65] 
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Table	6	–	Study	Characteristic	Table	(Saleh	et	al.	2015)	
 
Saleh et al. 2015  
Risk of Bias Moderate 
 
Groups dissimilar with respect to baseline confounding variables that were measured 
 
Study Design Retrospective Cohort Study 
Population 731 Patients 
Canada 
Multi-Center 
 
Inclusion criteria: Patients who underwent elective colorectal surgery with primary anastomosis between March 
2004 and December 2011 
 
Exclusion criteria: Patients who took any NSAID other than ketorolac within 5 days of surgery 
Intervention N = 355 
 
Intraoperative and/or postoperative ketorolac administered within 5 days of surgery 
 
Control N = 376 
 
No ketorolac received within the first 5 post-operative days 
Outcome Anastomotic Leak Rate  
 
Defined as a documented leak at the time of re-operation and/or radiologically confirmed based on contrast 
leakage or abscess at the site of the anastomosis with or without percutaneous drainage 
 
Secondary outcome: whether the total ketorolac 
dose received was associated with an increase in anastomotic leak rate. 
 
Results Intervention: 3.4% 
Control: 3.2% 
p>0.05 
Odds Ratio: 1.06 [0.47, 2.39] 
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Table	7	–	Study	Characteristic	Table	(Subendran	et	al.	2014)	
 
Saleh et al. 2015  
Risk of Bias Serious 
 
Not all potential confounding variables measured. 
 
Study Design Nested matched case-control study 
Population 262 Patients 
Canada 
Single-Center 
 
Inclusion criteria: All patients who had elective colorectal surgery at Mount Sinai Hospital in Toronto between 
January 2001 and June 2012  
 
Exclusion criteria: None given 
Cases N = 131 
 
Anastomotic leak postoperatively (within 12 months) as identified by radiologic investigations and/or direct 
confirmation at the time of re-operation  
Control N = 131 
 
1:1 matching with cases based on underlying disease, type of surgery, age (within 5 years), sex, and year of 
surgery (within 5 years) 
 
Exposure Primary Exposure: Any post-operative NSAID use within the first 5 days post-surgery  
 
Secondary Exposure: Use of ketorolac 
 
Results Cases: 52.7% exposed to NSAIDs 
Control: 44.3% exposed to NSAIDs 
p>0.05 
Odds Ratio: 1.40 [0.86, 2.28] 
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Appendix	
Appendix	 1	 –	 American	 Society	 of	 Anesthesiologists	 (ASA)	 Physical	 Status	
Classification	System48	
  
ASA 1 A normal healthy patient 
 
ASA 2 A patient with mild systemic disease 
 
ASA 3 A patient with severe systemic disease 
 
ASA 4 A patient with severe systemic disease that is a constant 
threat to life 
 
ASA 5 A moribund patient who is not expected to survive without 
the operation 
 
ASA 6 A declared brain-dead patient whose organs are being 
removed for donor purposes 
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Appendix	2	–	ERAS	guidelines	post	colorectal	surgery21		
Preoperative Period 
Education 
Counseling 
Optimization of medical comorbidities 
Mechanical bowel prep and oral antibiotics 
Fasting from fried or fatty foods or meat for eight hours 
Fasting from light meals and unclear liquids (eg, tea and toast, juice with pulp, milk) for six 
hours 
Fasting from clear liquids (excludes alcoholic beverages, beverages with milk, juice with pulp) 
for two hours 
No premedication 
Carbohydrate drink two hours prior to the procedure 
 
Intraoperative Period 
Thromboprophylaxis 
Antibiotic prophylaxis 
High-concentration inspired oxygenation 
Thoracic epidural analgesia 
Normothermia 
Fluid optimization 
Minimally invasive surgical approach 
No nasogastric tubes 
No intra-abdominal or perineal drains (except in settings such as colonic spillage or purulent 
drainage) 
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Postoperative Period 
Enteral nutrition beginning on day 1 
High-calorie supplements twice daily 
Opioid-sparing analgesia 
Multimodal antiemetic regimen 
Removal of urinary catheter, typically on postoperative day 1 
Mobilization using a structured program, typically on the evening of the procedure 
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Appendix	3	-	PRISMA	Checklist43	
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Appendix	4	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Bakker	et	al.	2016	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
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Appendix	5	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Gorissen	et	al.	2012	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
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Appendix	6	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Klein	et	al.	2009	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
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Appendix	7	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Klein	et	al.	2012	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info  
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Appendix	8	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Paulasir	et	al.	2015	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
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Appendix	9	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Saleh	et	al.	2014	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
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Appendix	10	–	Risk	of	Bias	Assessment	(ROBINS-I	Tool)	-	Subendran	et	al.	2014	
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For detailed information regarding scoring guidelines please refer to: 
 
Sterne JAC, Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions 
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from http://www.riskofbias.info 
 
